Sign in
HGENQ Stock Price, Chart, Stats & News
Humanigen, Inc.
Save
Humanigen, Inc. (HGENQ) does not currently pay a dividend.
23,816
Market cap
–
Current P/E
–
Forward P/E
HGENQ chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Humanigen, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies that prevent and manage an overactive immune response. At the forefront of its pipeline is lenzilumab, a monoclonal antibody designed to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF) by binding to it. This drug has been investigated for mitigating the cytokine storm in COVID-19 patients, having successfully completed a Phase 3 trial.
Similar securities
Based on sector and market capitalization
Report issue